Glycemic Treatment Navigator
ADA Standards of Care in Diabetes 2026, Section 9: Pharmacologic Approaches to Glycemic Treatment
Patient profile
Diabetes type
Heart failure
Special circumstance
Disease profile category
Type 2: glycemic-goal focus
Recommended
- Initial combination therapy (A1C ≥1.5% above goal): metformin plus a high-efficacy agent such as a GLP-1 RA or tirzepatide. (ADA 9.6)
Consider
- If injectable needed: GLP-1 RA/tirzepatide before basal insulin. Basal start 10 units/day or 0.1–0.2 units/kg/day, titrate about 2 units every 3 days to fasting goal. (ADA 9.21, Fig 9.5)
Avoid / caution
- DPP-4 inhibitor together with a GLP-1 RA or tirzepatide (no added benefit). (ADA 9.18)
Monitor / educate
- A1C is 1.5% above goal: do not delay intensification (therapeutic inertia). (ADA 9.15)
- If on an SGLT2i: sick-day plan, stop 3–4 days before surgery, watch for euglycemic DKA, genital infection, volume depletion. (ADA 9.39, Table 9.2)
- CGM if on insulin or hypoglycemia-prone agents; glucagon with insulin; DSMES and social determinants review; reassess every 3–6 months. (ADA 9.14, 9.24, 9.25, 9.28)
Decision support only. It summarizes ADA Standards of Care 2026, Section 9 and does not replace clinical judgment, drug labels, or local formularies.